BioCentury | Nov 12, 2012
Company News

Medical Research Council pharmaceuticals news

...London, U.K.) for its anti-inflammatory program; point-of-care diagnostic company OJ-Bio Ltd. (Newcastle, U.K.); cancer company Pharminox Ltd....
BioCentury | Jul 11, 2011
Financial News

Pharminox completes venture financing

Pharminox Ltd. , Oxford, U.K. Business: Cancer Date completed: 7/7/11 Type: Venture financing Raised: £1.5 million ($2.4 million) Investors: Existing investors; new investors WIR Staff...
BioCentury | Aug 9, 2010
Company News

Pharminox management update

Pharminox Ltd. , Oxford, U.K. Business: Cancer Hired: Marc Hummersone as research director Transitioning: Malcolm Stevens from CSO and a director to CSO emeritus WIR Staff cancer...
BioCentury | Jan 18, 2010
Company News

Pharminox board of directors update

Pharminox Ltd. , Oxford, U.K. Business: Cancer Appointed: Iain Ross as non-executive chairman; he replaces Mario Polywka, who stepped down, but remains a director WIR Staff cancer...
BioCentury | Jun 25, 2009
Strategy

Science for export

...U.K. Not available Particle Therapeutics Ltd. Drug delivery and reformulation 2006 Oxford, U.K. Not available Pharminox Ltd....
BioCentury | Sep 18, 2008
Distillery Therapeutics

This Week in Therapeutics

...additional cell lines and animal models are necessary to further validate the compounds' therapeutic potential. Pharminox Ltd.'s...
BioCentury | Jul 7, 2008
Company News

Pharminox board of directors update

Pharminox Ltd. , Oxford, U.K. Business: Cancer Appointed: Alan Miller, former chief investment officer of New Star Asset Management Ltd. WIR Staff cancer...
BioCentury | Dec 18, 2006
Company News

Pharminox, Schering-Plough deal

...Pharminox and SGP partnered to discover small molecule cancer therapeutics. Pharminox will synthesize compounds, which SGP...
...anti-tumor activity. SGP will have the exclusive option to license worldwide rights to resulting IP. Pharminox...
...than $40 million, including research funding for up to two years and milestones, plus royalties. Pharminox Ltd....
BioCentury | Apr 24, 2006
Company News

Pharminox, Cancer Research UK deal

...Cancer Research's Cancer Research Technology Ltd. subsidiary granted Pharminox an exclusive 12-month option to in-license exclusive...
...telomere signaling targeted agents. The lead compound, RHPS4 , is in preclinical development for cancer. Pharminox Ltd....
BioCentury | Aug 16, 2004
Company News

Pharminox, Cancer Research UK deal

...203). A U.K. Phase I trial of the compound is ongoing. Under a 2003 deal, Pharminox...
...and commercialization rights from Cancer Research to a series of preclinical quinols to treat cancer. Pharminox Ltd....
Items per page:
1 - 10 of 10
BioCentury | Nov 12, 2012
Company News

Medical Research Council pharmaceuticals news

...London, U.K.) for its anti-inflammatory program; point-of-care diagnostic company OJ-Bio Ltd. (Newcastle, U.K.); cancer company Pharminox Ltd....
BioCentury | Jul 11, 2011
Financial News

Pharminox completes venture financing

Pharminox Ltd. , Oxford, U.K. Business: Cancer Date completed: 7/7/11 Type: Venture financing Raised: £1.5 million ($2.4 million) Investors: Existing investors; new investors WIR Staff...
BioCentury | Aug 9, 2010
Company News

Pharminox management update

Pharminox Ltd. , Oxford, U.K. Business: Cancer Hired: Marc Hummersone as research director Transitioning: Malcolm Stevens from CSO and a director to CSO emeritus WIR Staff cancer...
BioCentury | Jan 18, 2010
Company News

Pharminox board of directors update

Pharminox Ltd. , Oxford, U.K. Business: Cancer Appointed: Iain Ross as non-executive chairman; he replaces Mario Polywka, who stepped down, but remains a director WIR Staff cancer...
BioCentury | Jun 25, 2009
Strategy

Science for export

...U.K. Not available Particle Therapeutics Ltd. Drug delivery and reformulation 2006 Oxford, U.K. Not available Pharminox Ltd....
BioCentury | Sep 18, 2008
Distillery Therapeutics

This Week in Therapeutics

...additional cell lines and animal models are necessary to further validate the compounds' therapeutic potential. Pharminox Ltd.'s...
BioCentury | Jul 7, 2008
Company News

Pharminox board of directors update

Pharminox Ltd. , Oxford, U.K. Business: Cancer Appointed: Alan Miller, former chief investment officer of New Star Asset Management Ltd. WIR Staff cancer...
BioCentury | Dec 18, 2006
Company News

Pharminox, Schering-Plough deal

...Pharminox and SGP partnered to discover small molecule cancer therapeutics. Pharminox will synthesize compounds, which SGP...
...anti-tumor activity. SGP will have the exclusive option to license worldwide rights to resulting IP. Pharminox...
...than $40 million, including research funding for up to two years and milestones, plus royalties. Pharminox Ltd....
BioCentury | Apr 24, 2006
Company News

Pharminox, Cancer Research UK deal

...Cancer Research's Cancer Research Technology Ltd. subsidiary granted Pharminox an exclusive 12-month option to in-license exclusive...
...telomere signaling targeted agents. The lead compound, RHPS4 , is in preclinical development for cancer. Pharminox Ltd....
BioCentury | Aug 16, 2004
Company News

Pharminox, Cancer Research UK deal

...203). A U.K. Phase I trial of the compound is ongoing. Under a 2003 deal, Pharminox...
...and commercialization rights from Cancer Research to a series of preclinical quinols to treat cancer. Pharminox Ltd....
Items per page:
1 - 10 of 10